Código QR (código de barras bidimensional)

Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation

Background/purpose: Three first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely available to treat advanced lung adenocarcinoma harboring EGFR mutation. However, studies comparing efficacy or effectiveness of these EGFR TKIs came out with inconclusive result...

ver descrição completa

Na minha lista:
Principais autores: Ming-Yi Huang, Kun-Pin Hsieh, Ru-Yu Huang, Jen-Yu Hung, Li-Tzong Chen, Ming-Ju Tsai, Yi-Hsin Yang
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-01-01
coleção:Journal of the Formosan Medical Association
Assuntos:
Targeted therapy
Effectiveness
Gefitinib
Erlotinib
afatinib
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S0929664621000760
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados